PT - JOURNAL ARTICLE AU - Gallon, Sebastian AU - Sy, Mouhamad AU - Tonto, Prince Baffour AU - Ndiaye, Ibrahima Mbaye AU - Toure, Mariama AU - Gaye, Amy AU - Aidara, Mariama AU - Mbaye, Amadou Moctar AU - Dia, Abdoulaye Kane AU - Diallo, Mamadou Alpha AU - Gomis, Jules Francois AU - Yade, Mamadou Samba AU - Diedhiou, Younous AU - Dieye, Baba AU - Diongue, Khadim AU - Seck, Mame Cheikh AU - Badiane, Aida S. AU - Ndiaye, Daouda AU - Herrera, Bobby Brooke TI - Seroprevalence of dengue, Zika, yellow fever and West Nile viruses in Senegal, West Africa AID - 10.1101/2024.11.21.24317738 DP - 2024 Jan 01 TA - medRxiv PG - 2024.11.21.24317738 4099 - http://medrxiv.org/content/early/2024/11/22/2024.11.21.24317738.short 4100 - http://medrxiv.org/content/early/2024/11/22/2024.11.21.24317738.full AB - West Africa serves as a critical region for the co-circulation of mosquito-borne flaviviruses, which often precipitate sporadic outbreaks. This study investigated the seroprevalence of dengue virus serotypes 1-4 (DENV-1-4), Zika virus (ZIKV), yellow fever virus (YFV), and West Nile virus (WNV) in three regions of Senegal: Sindia, Thies, and Kedougou. We retrospectively analyzed 470 serum samples for flavivirus immunoglobulin G (IgG) using a DENV-2 envelope (E) ELISA. Our findings revealed a seroprevalence of 37.23% for DENV-2 E IgG, indicative of a prior flavivirus exposure rate. The IgG seroprevalence rates for DENV-1-4, ZIKV, YFV, or WNV NS1 were 57.14%, 12.57%, 80.57% and 17.14%, respectively, with 72% of individuals harboring neutralizing antibodies against two or more flaviviruses. We also identified that residing in Sindia (ZIKV, OR, 9.428; 95% CI: 1.882-47.223 & WNV, OR, 6.039; 95% CI: 1.855-19.658) and Kedougou (ZIKV, OR, 7.487; 95% CI: 1.658-33.808 & WNV, OR, 1.142; 95% CI: 0.412-3.164) was a significant risk factor for ZIKV and WNV exposure. In contrast, history of malaria significantly reduced the risk of WNV exposure (aOR, 0.402; 95% CI: 0.203-0.794). This study underscores the complexity of flavivirus epidemiology in West Africa and the necessity for enhanced surveillance to inform public health strategies.Competing Interest StatementBBH is a co-founder of Mir Biosciences, Inc., a biotechnology company focused on T cell-based diagnostics and vaccines for infectious diseases, cancer, and autoimmunity.Funding StatementWe would like to thank Rutgers Global Health Institute, Rutgers Robert Wood Johnson Medical School, and The Child Health Institute of New Jersey for their continued support. The funders had no role in writing of the manuscript or decision to publish the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The samples included in our study were originally collected as part of malaria and non-malarial surveillance among residents of Sindia, Thies, and Kedougou, Senegal. Samples from Sindia and Thies were part of the surveillance of non-malarial febrile illnesses, while samples from Kedougou were part of genomic surveillance of malaria. Informed consent was obtained from all subjects and/or their legal guardians for the initial sample collection as well as for its future use. All methods were performed in accordance with the guidelines and regulations set forth by the Declaration of Helsinki. The primary studies under which the samples and data were collected received ethical clearance from the CIGASS Institutional Review Board (IRB) (Protocol numbers: SEN15/46, 19300, and SEN14/49). All excess samples and corresponding data were banked and de-identified prior to the analyses. This study received and exemption determination from the Rutgers Robert Wood Johnson Medical School IRB. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData produced as part of the current study are available in the manuscript or upon request from the corresponding author.